Literature DB >> 2553848

Analysis of peptide binding patterns in different major histocompatibility complex/T cell receptor complexes using pigeon cytochrome c-specific T cell hybridomas. Evidence that a single peptide binds major histocompatibility complex in different conformations.

H Bhayani1, Y Paterson.   

Abstract

The interaction of TCR, antigen, and MHC complex has been analyzed using synthetic peptide antigens and a series of single amino acid-substituted analogues. Two similar antigens, mouse cytochrome c (mcyt c) and pigeon cytochrome c (pcyt c), elicit T cell responses in strains of mice bearing MHC class II Ek beta Ek alpha (B10.A), Eb beta Ek alpha [B10.A(5R)], and Es beta Ek alpha [B10.S(9R)]. The immunogenic regions of these antigens are located in the peptide sequence p88-104 for pcyt c and m88-103 for mcyt c. The limited T cell repertoire for these antigens is comprised of four groups of T cell phenotypes that have very few differences in their TCR gene make up. In this paper, we examine the diversity in their fine specificity for each of the antigens, m88-103 and p88-104, complexed with each of the I-Ek haplotypes. Epitopes, i.e., residues that interact with the TCR, and agretopes, i.e., residues in the MHC-binding site, were assigned for the two peptide antigens in the presence of APC bearing E beta kEk alpha, Eb beta Ek alpha, or Eb beta Ek alpha using T cell hybridomas of the phenotypes I, IIIa, and IV. From our results, we conclude that first, the substitution of any residue between 95 and 104 of the cytochrome c peptide changed the antigenic potency of the peptide for at least one of the hybridomas. Second, each T cell type has a different recognition pattern of epitopes and agretopes for a particular antigen-MHC complex, thus, ruling out a static model of T cell recognition, which assigns certain, invariant agretopic residues to the peptide by which it interacts with the MHC molecule independently of the TCR. Third, the same T cell hybridoma responded to the antigens differently when presented on various MHC molecules, implying that overall changes in the MHC groove, as displayed by the three haplotypes, may affect the efficiency in binding the peptide. Fourth, since most of the residues are used as epitopes by at least one of the T cell specificities, the peptide appears to be recognized in a different conformation by each T cell hybridoma phenotype; and, finally, the epitopic and agretopic residues do not segregate, for any one of the T cell specificities, in such a way that suggests they are recognized in a helical conformation. In summary, our results suggest that a single peptide may generate diversity in the T cell response by virtue of its conformational flexibility within the TCR-MHC-antigen complex.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553848      PMCID: PMC2189495          DOI: 10.1084/jem.170.5.1609

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

2.  T-cell antigenic sites tend to be amphipathic structures.

Authors:  C DeLisi; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

Review 3.  T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex.

Authors:  R H Schwartz
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

4.  Functional analysis of the interaction of the antigen-specific T cell receptor with its ligands.

Authors:  J D Ashwell; B S Fox; R H Schwartz
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

5.  The T lymphocyte response to cytochrome c. V. Determination of the minimal peptide size required for stimulation of T cell clones and assessment of the contribution of each residue beyond this size to antigenic potency.

Authors:  R H Schwartz; B S Fox; E Fraga; C Chen; B Singh
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

6.  Identification of distinct predominant epitopes recognized by myoglobin-specific T cells under the control of different Ir genes and characterization of representative T cell clones.

Authors:  I Berkower; L A Matis; G K Buckenmeyer; F R Gurd; D L Longo; J A Berzofsky
Journal:  J Immunol       Date:  1984-03       Impact factor: 5.422

7.  The fine specificity of antigen and Ia determinant recognition by T cell hybridoma clones specific for pigeon cytochrome c.

Authors:  S M Hedrick; L A Matis; T T Hecht; L E Samelson; D L Longo; E Heber-Katz; R H Schwartz
Journal:  Cell       Date:  1982-08       Impact factor: 41.582

8.  Monoclonal antibodies against the antigen receptor on a cloned T-cell hybrid.

Authors:  L E Samelson; R N Germain; R H Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

9.  The Ia molecule of the antigen-presenting cell plays a critical role in immune response gene regulation of T cell activation.

Authors:  E Heber-Katz; D Hansburg; R H Schwartz
Journal:  J Mol Cell Immunol       Date:  1983

10.  Direct evidence that a class II molecule and a simple globular protein generate multiple determinants.

Authors:  P M Allen; D J McKean; B N Beck; J Sheffield; L H Glimcher
Journal:  J Exp Med       Date:  1985-10-01       Impact factor: 14.307

View more
  20 in total

1.  Highly conserved T-cell receptor junctional regions. Evidence for selection at the protein and the DNA level.

Authors:  S B Sorger; S M Hedrick
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

2.  Identification of a major I-Ek-restricted determinant of hen egg lysozyme: limitations of lymph node proliferation studies in defining immunodominance and crypticity.

Authors:  N J Viner; C A Nelson; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

3.  Evidence for cobinding of self- and allopeptides to human class II major histocompatibility antigen DR1 by energy transfer.

Authors:  H Kropshofer; H Max; H Kalbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

4.  Specific T cell recognition of kinetic isomers in the binding of peptide to class II major histocompatibility complex.

Authors:  J D Rabinowitz; K Tate; C Lee; C Beeson; H M McConnell
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

5.  Permissive recognition of a mycobacterial T-cell epitope: localization of overlapping epitope core sequences recognized in association with multiple major histocompatibility complex class II I-A molecules.

Authors:  D P Harris; H M Vordermeier; A Arya; C Moreno; J Ivanyi
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

6.  Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness.

Authors:  K Matsui; J J Boniface; P Steffner; P A Reay; M M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

7.  Negative selection of CD4+ CD8+ thymocytes by T-cell receptor peptide antagonists.

Authors:  D M Page; J Alexander; K Snoke; E Appella; A Sette; S M Hedrick; H M Grey
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

8.  Enhancement of peptide antigen presentation by a second peptide.

Authors:  A I de Kroon; H M McConnell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

9.  Haplotypic origin of beta-chain genes expressed by human T-cell clones.

Authors:  E Seboun; N Joshi; S L Hauser
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

10.  Regulation of the immune response to peptide antigens: differential induction of immediate-type hypersensitivity and T cell proliferation due to changes in either peptide structure or major histocompatibility complex haplotype.

Authors:  P Soloway; S Fish; H Passmore; M Gefter; R Coffee; T Manser
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.